News

These data suggest that physical activity interventions can lead to visible improvements in PASI scores after 20 weeks of implementation, as well as cardiometabolic improvements.

Axatilimab was awarded approval for the treatment of chronic GVHD in adult and pediatric patients who failed ≥2 prior lines of systemic therapy.

Investigators highlight the need for tailored interventions to improve sleep disturbances and overall health in patients with hepatocellular carcinoma.

The accelerated approval is based on phase 3 data demonstrating seladelpar’s impact on ALP reduction and is contingent upon verification and description of clinical benefit in confirmatory trial(s).

These data show that izokibep treatment of HS met each of its key primary and key secondary endpoints.

A retrospective analysis compared data from the BE OPTIMAL and BE COMPLETE trials with data from pivotal trials of the IL-23–targeting therapies.

A ranibizumab biosimilar lowers costs compared with aflibercept across all nAMD subtypes from both the patient and societal perspectives.

This analysis was conducted to evaluate the effect of pruritus on quality of life ratings among individuals with atopic dermatitis and psoriasis.

Deepak Bhatt, MD, MPH, MBA, discusses 7 trials to watch from hotline or late-breaking sessions at the upcoming European Society of Cardiology Congress 2024.

Noureddin explains the discordance between FIB-4 and transient elastography for stratifying fibrosis risk and emphasizes the importance of repetition and attentiveness with FIB-4.

The study was not adequately powered to assess a significant association with cancer mortalities.

Preliminary Phase 1b data demonstrated the favorable safety and tolerability profile of VLS-01 buccal film, with psychedelic effects resolved by 120 minutes.

In this analysis, the biggest predictors of biologic initiation among individuals with diagnoses of psoriasis were evaluated.

Findings suggest increased intensity of IgM deposits in patients with positive IgM deposition may contribute to adverse clinicopathologic presentation and clinical outcomes.

New study suggests MRI-derived pressure measurements indicate a 5-fold increase in heart failure risk.

Adalimumab-aaty was FDA approved on May 23, 2023, and became commercially available in the US on July 2, 2023.

Announced by Rivus Pharmaceuticals, HU6 met its primary endpoint of weight reduction in patients with obesity-related HFpEF in a Phase 2a trial.

Adding vitrectomy with ILM peeling to a treat-and-extend anti-VEGF therapy showed no benefit on visual or anatomic outcomes in DME treatment.

The drug is the first approved monoclonal antibody specifically designed to inhibit the IL-31 pathway, a driver of prurigo nodularis.

This analysis highlights data regarding agreement between various smartphone applications used for detection of melanoma.

Laurence Sperling, MD, provides an overview of the Family Heart Global Summit, including previewing the meeting and discussing where interested attendees can learn more.

Findings highlight a 78.4% treatment success rate among patients who prematurely discontinued DAAs, reaching 93.5% among those who discontinued after week 4.

Similar trends were seen in study participants that transitioned from receiving placebo to bimekizumab after study week 16.

Ravulizumab therapy may enable patients with PNH to achieve activity and patient-reported outcomes comparable to the US general population.

Maintaining stable HbA1c levels in target ranges reduces Alzheimer Disease risk in older adults with diabetes, emphasizing the importance of personalized glycemic control.

In this interview, Kim speaks about the significance of the FDA approval of neffy for patients who face the threat of anaphylaxis and other severe allergic reactions.

The updated pediatric IgAN prediction tool allows clinicians to assess risk of disease progression 1-2 years post-biopsy.

Cristina Pearse, an MDMA-assisted therapy trial participant, expresses disappointment in the FDA’s decision not to approve MDMA-assisted therapy.

A new real-world study suggests tirzepatide provides greater reductions in mortality, cardiovascular risk, and kidney events than GLP-1 receptor agonists in type 2 diabetes.

Adjusted analyses reveal a statistically significantly higher prescription medication cost in patients with RA compared to those without.